Medscape Education is supporting a dedicated AI symposium at the 2026 European Hematology Association (EHA) Annual Congress ...

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

In a 500-patient phase 3 trial, daraxonrasib extends median overall survival to 13.2 vs 6.7 months for chemotherapy in second-line metastatic pancreatic cancer.

The collaboration enhances Medscape's oncology resources with additional expert-validated insights to help clinicians navigate an increasingly complex cancer care landscape across all platforms NEWARK ...

Landmark symposium to equip clinicians with practical, ethical AI frameworks, chaired by a lead author of Europe's oncology guidelines.